The Directory of Pharma Companies and News

Motif Bio

Motif a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.

Motif Bio News

2016-09-15Poster Presentation at ID Week
2016-09-14Issue of Equity
2016-09-08Update on Revive-1 Phase 3 Clinical Trial
2016-09-08Re-negotiation of the terms of the Convertible Promissory Notes
2016-08-26Chief Medical Officer to present at the World Anti-Microbial Resistance Congress
2016-08-16Second Quarter and Half-Year 2016 Financial Results and Operational Progress
2016-08-09Update on Timing of Motif Bio Proposed U.S. Public Offering of American Depositary Shares and Application for Nasdaq Lis...
2016-08-01Result of General Meeting
2016-04-28Amphion Innovations plc
2016-04-25Analyst & Investor conference call
2016-04-22Grant of share options to senior management
2016-04-21Annual Report and Accounts 2015 available on website
2016-04-20Final Results for the year ended 31 December 2015
2016-04-18Notice of Results
2016-04-14Motif Bio makes new senior appointments
2016-03-23Motif Bio to present at BIO-Europe Spring
2016-03-14Appointment of strategic adviser
2016-03-09Motif’s Dr. David Huang on Nature’s “Combating Antibiotic Resistance” Webcast
2016-03-02First patient dosed in iclaprim Phase 3 trials to treat skin infections
2016-02-23Notification of Major Interest in Shares
2016-02-22Motif Bio to participate in Webcast on Combating antibiotic resistance
2016-01-25Appointments of U.S. corporate finance adviser and auditor
2015-12-22Exercise of Warrants
2015-12-15Iclaprim Clinical Trial Supplies Manufactured
2015-12-07Motif selected to present at Biotech Showcase, San Francisco, January 2016
2015-11-24Receipt of FDA Concurrence with Optimized Dose for Iclaprim Phase III Clinical Trials
2015-11-11European Agreement for Iclaprim Phase III Clinical Development Programme
2015-10-27Selected to Present at BIO-Europe 2015
2015-10-16Contract Signed With Leading CRO to Conduct Iclaprim Phase III Clinical Trials
2015-10-13Announces Results of Two Posters on Iclaprim at ID Week 2015
2015-10-05Directors Dealings
2015-09-29Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015
2015-09-23Issue of Shares for Exercised Warrants
2015-09-03FDA Grants Fast Track Designation for Iclaprim
2015-09-02Motif Appoints Westwicke Partners as Investor Relations Adviser in U.S.
2015-09-02Participation at Upcoming Investor Events
2015-08-27Interims Results for the Six months to 30 June 2015
2015-08-24Potent Efficacy of Iclaprim Confirmed in Independent Laboratory Study
2015-07-22FDA QIDP Designation for Motif’s Lead Antibiotic Candidate Iclaprim for ABSSSI
2015-07-22Final condition of £22 million placing satisfied with FDA QIDP Designation for iclaprim
2015-07-20Exercise of Options
2015-07-17FDA QIDP Designation for Motif’s Lead Antibiotic Candidate Iclaprim for HABP
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.